Fig 1: Clinical presentation of hemolytic–uremic syndrome (HUS) in mice exposed to different Shiga toxin (Stx) application regimes. (A–C) C57BL/6J mice received either a single high dose of 300 ng/kg Stx (Stx acute) or vehicle (sham). Blood was taken at the end of the experiment, 2 days after the induction of HUS (B, C). (A) Weight loss percentage of body weight (sham n = 10, Stx acute n = 11). (B) Plasma levels of creatinine and urea (sham n = 10, Stx acute n = 9) and neutrophil gelatinase-associated lipocalin (NGAL) (sham n = 10, Stx acute n = 10). (C) Platelet count, hemoglobin, and hematocrit (sham n = 10, Stx acute n = 10) (D–F). Mice received either two lower doses of 25 ng/kg Stx (Stx subacute) spaced 72 h apart or vehicle (sham). Blood was taken at end of the experiment, five days after the induction of HUS (E, F). (D) Weight loss percentage of body weight (sham n = 10, Stx subacute n = 10). (E) Plasma levels of creatinine and urea (sham n = 10, Stx subacute n = 9) and NGAL (sham n = 10, Stx subacute n = 10). Platelet count, hemoglobin, and hematocrit (sham n = 10, Stx subacute n = 10). (A–F) Data are presented as scatter dot plot with mean ± SD for n number of observations, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 vs. the corresponding sham group (A, D: two-way repeated measures ANOVA, Bonferroni’s multiple comparison test; all other: Mann–Whitney U test).
Supplier Page from BioLegend for LEGEND MAX(TM) Mouse NGAL (Lipocalin-2) ELISA Kit